Clotrimazole: no significant risks listed in the Klofan cream risk management plan

What is described

The supplied abstract describes the risk management plan for Klofan vaginal cream, which contains clotrimazole. The document focuses on safety measures, routine risk minimization, and ongoing pharmacovigilance. It describes an approach to managing product safety rather than results from a clinical efficacy study or a comparison with other treatments.

Key points

According to the abstract, the plan lists no significant identified or potential risks or missing safety information. There are currently no obligations to conduct post-marketing studies. Nevertheless, routine pharmacovigilance and routine risk minimization activities are to continue.

The plan described is consistent with the safety information in the product’s summary of product characteristics. The abstract does not detail specific measures, adverse reaction frequencies, or data for particular patient groups.

Meaning for practice

The practical reference is adherence to the product’s safety information. The absence of significant risks in the plan summary should not be interpreted as evidence that adverse reactions cannot occur. Link to the document.